Effect of Intraperitoneal Insulin Administration After Laparoscopy in Insulin-Resistant Patients on Prevention of Postoperative Adhesion Recurrence: A Randomized Controlled Trial

What Was Tested

In this not phased trial, researchers set out to test Insulin (regular human) for insulin resistance, prediabetes & type 2 diabetes.

Patients with insulin resistance (IR) may have heightened inflammatory responses and impaired tissue healing, contributing to a higher risk of adhesion formation.

It had two arms (groups): Intervention group (active comparator) and Control group (sham comparator).

The registry classes the interventions as drug.

More on the Plan

The study will be conducted at a dr saed hospital and will enroll 100 female patients diagnosed with insulin resistance undergoing laparoscopy for infertility or chronic pelvic pain.

Who Took Part

Enrollment: 100 planned participants were the target.

It was open to women only aged from 18 years up to 50 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Women aged 18-40 years. Diagnosed insulin resistance (e.g., HOMA-IR \>2.5 or fasting insulin \>15 uIU/mL). Indicated for laparoscopy for infertility or pelvic pain. BMI 20-35 kg/m². Able and willing to give informed consent.

The full record lists 5 inclusion and 6 exclusion criteria; among the exclusions: history of peritonitis or major abdominal surgery in the past 6 months; known allergy or sensitivity to insulin; chronic steroid or immunosuppressive use.

How the Study Was Run

Design: randomized, parallel-group and quadruple-blind.

The insulin resistance, prediabetes & type 2 diabetes participants were allocated by chance, so the Insulin (regular human) group and the comparison group should start out alike.

Groups ran in parallel: each of the insulin resistance, prediabetes & type 2 diabetes participants stayed in one arm throughout.

Blinding on both sides kept the insulin resistance, prediabetes & type 2 diabetes participants and researchers unaware of who received Insulin (regular human).

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2025-06-01 with completion listed for 2026-03-01.

Its stated primary purpose is prevention.

What Was Measured

Researchers chose this as the main measure: Adhesion scoring at second-look laparoscopy (time frame: 4-6 weeks postoperatively).

It also tracked 4 secondary outcomes, for example Postoperative pain scores, Hypoglycemic events, Hypoglycemic events and Fertility rates.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Insulin (regular human) in 100 people with insulin resistance, prediabetes & type 2 diabetes.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin (regular human) compound page, Insulin resistance, prediabetes & type 2 diabetes research.